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AbstrACt
Introduction Prevalence of suicidal ideation (SI) and 
behaviours are higher among patients with cancer than 
general population. No systematic review/meta-analysis 
investigated this topic; therefore, our aim will be to assess 
the relationship between cancer and SI and behaviours.
Methods We will search PubMed/MEDLINE, EMBASE, 
SCOPUS, Web of Science, PsycINFO and Cochrane Library 
databases from their inception until 30 June 2018. Case–
control and cohort studies focused on the association 
between cancer (any type) and suicidal outcomes (suicide, 
suicide attempt and SI) will be included. Two team 
members will independently: (A) perform the selection 
of the included studies and data extraction, with the 
supervision of a third member in case of discrepancies and 
(B) assess each study with: (1) Newcastle-Ottawa Scale 
(NOS); (2) Strengthening the Reporting of Observational 
Studies in Epidemiology (STROBE) statement; (3) Grading 
of Recommendations Assessment, Development and 
Evaluation (GRADE). We will conduct a random-effects 
meta-analysis. Individual and pooled ORs and associated 
95% CIs will be calculated as well as between-study 
heterogeneity. We will examine the potential for publication 
bias. If possible, we will explore reasons for potential 
between-study heterogeneity.
Ethics and dissemination This study does not require 
ethical approval. The study will be submitted to a peer-
reviewed journal, will be publicly disseminated and will be 
the topic of research presentations.
PrOsPErO registration number CRD42017072482.
IntrOduCtIOn  
In 2015, cancer was the second leading 
cause of death worldwide,1 and suicide was 
the 17th cause of death and the second 
among 15–29 year olds.2 Cancer might also 
lead to suicide: prior studies have shown 
that suicide incidence among patients with 
cancer is almost double compared with the 
general population.3–5 Moreover, patients 
with cancer were found to be particularly 
prone to suicidal ideation (SI), especially in 
the case of advanced cancer,4 5 and suicide 
attempts (SAs)5 6 as well. However, little is 
known about: (1) the timing of suicide risk 
following a cancer diagnosis; (2) whether 
findings are consistent across different popu-
lations and (3) the shared risk factors.
1. Concerning the timing of risk following 
the cancer diagnosis, one study reported 
that standardised mortality ratio (SMR: the 
ratio of observed deaths in the study group 
to expected deaths in the general popula-
tion) was 3.09 for men and 2.18 for women 
within the first 5 months after diagnosis; 
during 12–23 months after cancer diagno-
sis, SMR decreased but remained elevated 
to 1.57 and 1.72, respectively.7 In another 
study, risk of suicide was highest during the 
first 3 months for men, while highest from 3 
to 12 months for women.8 Such difference 
can be explained by different prognosis, 
in particular to poor prognosis in the first 
peak (3 months) and to moderate–good 
prognosis in the second risk increase (12–
14 months)9 ; the last peak of risk elevation 
has been explained by the possible cancer 
recurrence after the failure of treatment. 
Moreover, patients with prostate cancer 
seem to be particularly at risk of suicide af-
ter 15 years since the cancer diagnosis.10 11 
This finding has been tentatively interpret-
ed with late-onset metastases and/or symp-
toms, long-term urinary incontinence and 
erectile dysfunctions.11 Hence, suicide risk 
strengths and limitations of this study
 ► This will be the first systematic review and me-
ta-analysis on the topic.
 ► Implications of our future findings might provide 
evidence to the improvement of policies on suicid-
al symptom screening by healthcare professionals 
working in oncology.
 ► The findings could be limited to determine the tim-
ing of suicide risk after a cancer diagnosis and the 
specific cancer sites associated with suicide due to 
the less investigation from previous studies.
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may shift, from being related to psychological effects 
linked to the diagnosis in the short term, to being asso-
ciated to cancer-related sequelae, side effects of cancer 
treatment, fear of cancer recurrence and further age-
ing-related factors in the long term.10
2. Concerning consistency across populations, gender, 
age, income and regional differences have been report-
ed. Male patients with cancer seem to have a higher 
suicide risk than females.5 The highest suicide risk was 
reported among people aged 40–46 and over 60 years.5 
Among patients with cancer, higher income was asso-
ciated with less SI.12 Regional differences were also 
found: the association between cancer and suicide was 
found to be stronger in Eastern European nations.13 
Authors hypothesised that this association could be 
related to indicators of social disintegration (such as 
divorce, abortion and illegitimacy rates, and urbanici-
ty) but only in less developed regions (eg, Ukraine vs 
USA).14 15 Accordingly, living alone, further indicator 
of social disintegration, is associated with suicide.16
3. Pertaining risk factors, SI and behaviours seem to be 
linked to the same risk factors in patients with cancer 
and in the general population: male gender, older age, 
depression, hopelessness, pain and poor physical func-
tioning. In particular, depressive disorders (including 
major depression, minor depression and other forms 
of depressive conditions, such as demoralisation) affect 
up to 60% of patients with cancer.17 However, depres-
sion in these patients could not be recognised because 
it could be hard to distinguish depressive symptoms 
from some cancer treatment-related and cancer dis-
ease-related symptoms, such as fatigue.18 Further risk 
factors for suicide among individuals diagnosed with 
cancer include the already described time since diag-
nosis, cancer site, advanced stage of cancer at diagnosis 
and poor prognosis.4 5 The majority of studies did not 
examine specific cancer types and some pooled togeth-
er more severe forms of cancer, such as oesophagus, liv-
er, pancreas and lung cancers.3 Although disease with 
advanced stage and poor prognosis seem to be linked 
to higher suicide risk, increased suicide risk was also 
observed in patients with low-risk prostate cancer.19
In particular, shared risk factors (eg, smoking, alcohol 
consume and air pollution) might lead to spurious as-
sociations between cancer and suicide conditions.20–23 
The evaluation of other factors, such as pain24–26 and 
social support,27 28 may also help in the identification 
of new targeted prevention strategies.
To our knowledge, no previous systematic review and 
meta-analysis investigated the association between a 
cancer diagnosis and suicide risk. Thus, the aim of this 
study is to assess the risk of SIs and behaviours after a 
cancer diagnosis. Secondary aim of this study will be to 
specifically address the knowledge gaps in the previous 
literature, focusing on the timing of suicide risk and 
controlling for all the possible confounding factors. 
We will focus not only on suicide but also on SI and 
SAs since they are risk factors for suicide.29 Our future 
findings might shed further light on the improvement of 
on-time suicidal symptom screening among patients with 
cancer. For instance, healthcare professionals working in 
oncology should receive specific training to identify and 
treat depression and SI and behaviours.
ObjECtIvEs
To investigate the association between cancer diagnosis 
and
1a. Suicide,
1b. SA,
1c. SI.
These analyses will be performed controlling for 
confounding factors when possible.
MEthOds
The present protocol has been registered in PROS-
PERO and is reported in accordance with the Preferred 
Reporting Items for Systematic Review and Meta-Analysis 
Protocols statement.30
The meta-analysis will be reported in accordance with 
the reporting checklist proposed by the Meta-analysis of 
Observational Studies in Epidemiology group.31
types of studies
Studies will be included if: they are case–control and both 
prospective and retrospective cohort studies of any length 
of follow-up; they investigate the association between 
cancer diagnosis and subsequent SI and behaviours; they 
report data on cancer diagnoses and suicidal outcomes; 
they focus on any type of study population. If available, 
we will use estimates of the association (ORs, risk ratios or 
rate ratios) and 95% CIs that have accounted for poten-
tial confounders; otherwise, we will include data on the 
number of cases and non-cases with and without cancer 
diagnoses to calculate crude estimates of the associa-
tion, and we will conduct sensitivity analyses restricted to 
adjusted estimates.
Studies will be excluded if: they are not written in English; 
they focus on patients with cancer only or suicidal patients 
only; they pool different suicidal outcomes together (eg, 
suicide and SA) and separate data are not available after 
having contacted the authors; they rely on self-reported 
cancer diagnoses only; they are randomised controlled 
trials, because we aimed to exclude the potential bias of 
treatment interventions; they are cross-sectional studies, 
because we focus on suicide risk after cancer diagnosis.
types of participants
We will include studies of subjects regardless of age, sex or 
ethnicity who were participants in observational studies 
(case–control and cohort) from inpatient, outpatient or 
mixed community settings with any cancer diagnosis.
Cancer
We will include studies that examine the impact of a 
diagnosis of any malignant neoplasm (International 
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Classification of Diseases (ICD)-9: 140–209; ICD-10: C00–
C97). In sensitivity analyses, we will consider site-specific 
cancers if sufficient data are available.
Suicidal outcomes
We will refer to established nomenclature.29 We will 
separately consider all the suicidal events as reported by 
the original study authors: suicide (self-inflicted death), 
SA (self-inflicted potentially injurious behaviour with a 
non-fatal outcome and with the intention to die) and SI 
(thinking of dying of suicide). If possible, we will consider 
the distinction between passive SI (eg, thoughts of being 
better off dead) and active SI as well. We will include 
deliberate self-harm only if it is possible to distinguish 
non-suicidal self-injury (NSSI) and SA (NSSI refers to 
an intentional act of causing physical injury to oneself 
without wanting to die). As outcomes, we will consider 
the number of events (suicide and SA) and any stan-
dardised rating scale for assessing the presence of SI; it 
could be an item as for Montgomery–Åsberg Depression 
Rating Scale32 or Hamilton Rating Scale for Depression,33 
or a specific scale about suicide, like the Columbia-Sui-
cide Severity Rating Scale.34 We will consider SI as pres-
ence versus absence. If only mean score measures of SI 
are shown in an article, we will contact the authors.
search methods for the identification of studies
Electronic searches
We will search PubMed/MEDLINE, EMBASE, SCOPUS, 
Web of Science, PsycINFO and Cochrane Library, from 
their inception until 30 June 2018, to identify cohort and 
case–control studies reporting the association between 
cancer and suicidal outcomes. Combinations of Medical 
Subject Headings terms will be: [cancer* OR tumor* OR 
carcinoma* OR neoplas* OR oncolog* OR metastas* OR 
malign*] AND [suicid* OR self-harm* OR self harm OR 
self-poisoning OR self poisoning] (see online supplemen-
tary document 1).
Reference lists
The reference lists of all the included studies, relevant 
papers and previous systematic reviews will be also hand-
searched for the identification of additional studies.
data collection
Selection of studies
Two authors (RC and QS) will independently check the 
titles and abstracts of all the references generated by the 
search strategies to decide if they meet the inclusion 
criteria. All studies potentially eligible for inclusion will 
be added to the preliminary list, and their full-text arti-
cles will be retrieved. The two authors will then assess all 
full-texts to verify if they meet the inclusion criteria. If 
the authors disagree, the final decision will be made by 
consensus with the involvement of FF, EM or AC.
Data extraction and management
Using a standardised data extraction sheet, RC and 
QS will independently extract data from the included 
studies. Any disagreement will be discussed with a third 
member of the review team (FF, EM or AC), and deci-
sions will be documented. In the case of missing informa-
tion concerning the outcomes of interest, we will directly 
contact study authors up to three times to obtain addi-
tional information.
The following data will be extracted from all studies 
meeting the inclusion criteria: country, study design, year, 
sample size and type, period of assessment, hazard period 
(ie, the assessed time period after the cancer diagnosis), 
suicide outcomes, percentage of males, age, ethnicity, 
cancer type, main results, list of confounders included in 
design and analysis, crude numbers and measure of asso-
ciation (ORs) and 95% CIs, and data source.
When available, we will consider both raw data and the 
models adjusted for covariates. If a study conducts one 
analysis of men and one of women, those will be included 
as two separate studies.
In the case of studies published on the same data 
source, we will use the most recently published results or 
the largest sample size. To avoid the risk of overlapping 
studies for each study, we will extract: (1) the names of 
the authors and (2) the names of the databases/studies 
(data source) and we will check for duplicates; then, in 
the case of doubts, we will contact the authors.
Assessment of quality, strength of reporting and certainty of 
evidence in included studies
Two authors (RC and VEDM) will independently assess 
the quality of the studies using the Newcastle-Ottawa Scale 
(NOS)35 and the strength of reporting of studies according 
to the Strengthening the Reporting of Observational 
Studies in Epidemiology (STROBE) statement.36 The NOS 
assesses with eight questions the quality of case–control and 
cohort studies in three broad categories: (1) patient selec-
tion; (2) comparability of study groups; (3) assessment of 
the outcome. The STROBE statement consists of a 22-item 
checklist for the assessment of the strengths and weaknesses 
of each section of a single study (title, abstract, introduc-
tion, methods, results and discussion). The Grading of 
Recommendations Assessment, Development and Evalu-
ation (GRADE) methodology for evaluating the certainty 
of evidence for each outcome will be used as well.37 The 
certainty of evidence will be classified as high (further 
research is very unlikely to change our confidence in the 
estimate of effect), moderate (further research is likely to 
have an important impact on our confidence in the esti-
mate of effect and may change the estimate), low (further 
research is very likely to have an important impact on our 
confidence in the estimate of effect and is likely to change 
the estimate) or very low (any estimate of effect is very 
uncertain).
data analysis
Main analyses
We will calculate pooled ORs and 95% CIs. We will 
assess heterogeneity with the  χ2 goodness of fit and 
I2 statistics. Concerning I2, we will consider Cochrane 
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recommendations.38 We will consider statistically significant 
a p value <0.05 (presence of heterogeneity). In the case of 
the presence of heterogeneity, we will perform sensitivity 
analyses and metaregressions when possible.
We will use a random-effects model since we hypothesise 
that the effect will be similar but not identical across studies. 
A funnel plot will be created to reveal the preferential publi-
cation of statistically significant results. Tests for funnel plot 
asymmetry will be used in the presence of at least 10 studies. 
The Egger’s test will be also used to evaluate the funnel plot 
asymmetry.39
Additional analyses
We would like to calculate the pooled prevalence for each 
suicidal outcome in subjects with and without cancer. 
Moreover, if there is a sufficient number of studies for each 
suicidal outcome, we will investigate potential sources of 
heterogeneity using metaregression models, and we will 
perform subgroup analyses by sociodemographic (eg, age, 
sex, ethnicity, socioeconomic status, social support) and 
clinical characteristics (eg, smoking and other substance 
use, physical disorders, pain, cancer type, cancer stage (0, I, 
II, III and IV), early and late suicide (early suicide: suicide 
during the first year after the cancer diagnosis)) and by 
study design (case–control and cohort). If possible, we will 
also compare subjects died by suicide to subjects died by 
accidental causes (myocardial infarction, road traffic and 
motor vehicle accidents, homicide, domestic and indus-
trial accidents or any other external cause) as a secondary 
outcome. If sufficient data are available, we will perform a 
subgroup analysis on adult cancer survivors only.
Further potential points of discussion
Even if it might be outside of the scope of this study, consid-
ering the constant increase of the number of patients 
requesting Euthanasia or Assisted Suicide (EAS) in coun-
tries where this procedure is allowed40 is mandatory. So, we 
will also take into account this issue, trying to differentiate 
between patients with cancer with a terminal condition and 
patient with a better prognosis requesting EAS.
Software
All analyses will be conducted in Stata V. 14.
Patient and public involvement
Patients and/or public were not involved.
strengths and limitations of this study
To our knowledge, this will be the first systematic review and 
meta-analysis investigating the relationship between cancer 
and SI and behaviours. The implications of our future find-
ings might provide evidence to the improvement of policies 
on suicidal symptom screening by healthcare professionals 
working in oncology.
Limitations mainly included the lack of investigation 
on specific topics: the number of studies investigating 
the timing of suicide risk following a cancer diagnosis, 
and specific cancer sites associated with suicide could be 
limited; also, it could be difficult to distinguish depressive 
symptoms from some cancer treatment-related and cancer 
disease-related symptoms.
Ethics and dissemination
No ethical approval is required to perform this study. We 
will publish results in a peer-reviewed scientific journal and 
data set will be made freely available.
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